Abstract 3264
Background
A subgroup of MEK1 mutations in human tumors were recently described as RAF- and phosphorylation independent and as insensitive to currently clinically used allosteric MEK inhibitors. We established a novel cell line that carries a MEK1 mutation of this class (pGlu102_Lys104delinsGln) and tested a novel ATP competitive MEK inhibitor (MAP855) in this model. According to our knowledge this is the first patient derived cell line with this type of MEK mutation and the first spitzoid melanoma cell model.
Methods
PF130 cell line was established from the pleural effusion sample of a 37-year-old male patient with spitzoid melanoma. NGS was used for mutational analysis. Cells were treated either with allosteric MEK inhibitor selumetinib or with newly developed ATP competitive MEK inhibitor MAP855. We analyzed changes in cell number, cell cycle distribution and ERK activation after treatment in vitro. Furthermore, the in vivo tumorigenicity was tested by injecting the cells subcutaneously, intrapleurally or intravenously into female SCID mice.
Results
We found that ATP competitive MEK inhibitor MAP855 strongly decreased the viability of PF130 cells, while allosteric inhibitor selumetinib did not. Cell cycle analysis showed that MAP588 treatment could induce cell death in PF130 cells in a concentration dependent manner and slightly reduced the amount of cells in the S and the G2M phases. Furthermore, MAP855 was able to reduce ERK protein activation in PF130 cells effectively while selumetinib treatment had no effect. In vivo, intrapleurally injected cells established macroscopic tumors in the chest cavity after two months while intravenously and subcutaneously delivered cells showed limited growth.
Conclusions
We established a new cellular model of tumors with RAF- and phosphorylation independent MEK mutation. We found that recently developed ATP-competitive MEK inhibitor MAP855 is a potent inhibitor of these cells in vitro. The in vivo efficacy is currently under investigation. Furthermore, we describe here to the best of our knowledge the first patient derived spitzoid melanoma cell model to test both in vitro and in vivo novel therapeutic modalities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Balazs Hegedus.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract
3842 - Effect of docetaxel-resistance on the reactivity of prostate cancer cells to metformin
Presenter: Jessica Catapano
Session: Poster Display session 3
Resources:
Abstract
5198 - Cell plasticity and taxanes resistance in metastatic prostate cancer: ESRP1 as a predictive biomarker of taxane response
Presenter: Natalia Jimenez
Session: Poster Display session 3
Resources:
Abstract
2981 - Effect of Selumetinib plus AZD8186 treatment on Cabazitaxel sensitivity in docetaxel-acquired resistant metastatic prostate cancer cell lines
Presenter: Vicenc Ruiz de Porras
Session: Poster Display session 3
Resources:
Abstract
2779 - Anti-tumor activity of cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, in pancreatic ductal adenocarcinoma cells
Presenter: Majid Momeny
Session: Poster Display session 3
Resources:
Abstract
1782 - The molecular mechanisms of EpCAM in regulating tumor progression and development of anti-EpCAM antibodies for colon cancer diagnosis and therapy
Presenter: Han-chung Wu
Session: Poster Display session 3
Resources:
Abstract
1322 - Detection of microRNAs as biomarker for anti-EGFR antibody resistance in colon cancer patients
Presenter: Jens Hahne
Session: Poster Display session 3
Resources:
Abstract
1579 - Serum exosomal microRNA-199b-5p as a novel circulating biomarker to predict response of preoperative chemoradiotherapy for locally advanced rectal cancer
Presenter: Dong Won Baek
Session: Poster Display session 3
Resources:
Abstract
1761 - Live biobank of patient-derived organoids from Thai colorectal cancer patients enables clinical outcome prediction
Presenter: Pariyada Tanjak
Session: Poster Display session 3
Resources:
Abstract
3542 - The biological implications of PDCD6 dysregulation in colorectal cancer
Presenter: Romina Briffa
Session: Poster Display session 3
Resources:
Abstract